Pharm'Up 
In India, Colozo® is specifically approved for the treatment of Chronic Idiopathic Constipation (CIC) in adults. This condition is characterized by infrequent bowel movements, hard stools, and a feeling of incomplete evacuation, with no identifiable underlying cause. CIC can significantly impact a person’s quality of life and is often managed with lifestyle changes, dietary fiber, and over-the-counter laxatives. The launch of Colozo® provides a novel, evidence-based treatment option for patients who haven’t found relief with existing therapies.
M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, highlighted the importance of this launch: “The launch of Colozo® marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs… Backed by robust clinical evidence and promising outcomes, Colozo® represents a breakthrough in addressing unmet needs of patients and enhancing their quality of life.”
About the Author
